{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:10:41Z","timestamp":1790727041103,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union's 7th Framework Program","award":["324487"],"award-info":[{"award-number":["324487"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00330-018-5737-z","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T13:54:13Z","timestamp":1538402053000},"page":"1922-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem\u00ae) examinations, including 3,209 performed on renally insufficient individuals"],"prefix":"10.1007","volume":"29","author":[{"given":"Laura K.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona Z.","family":"Matthew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Graeme","family":"Houston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"5737_CR1","doi-asserted-by":"publisher","unstructured":"Port M, Id\u00e9e JM, Medina C, Robic C, Sabatou M, Corot C (2008) Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21:469\u2013490. https:\/\/doi.org\/10.1007\/s10534-008-9135-x","DOI":"10.1007\/s10534-008-9135-x"},{"key":"5737_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/RLI.0000000000000276","volume":"51","author":"E Kerviler de","year":"2016","unstructured":"de Kerviler E, Maravilla KR, Meder JF et al (2016) Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Invest Radiol 51:544\u2013551. https:\/\/doi.org\/10.1097\/RLI.0000000000000276","journal-title":"Invest Radiol"},{"key":"5737_CR3","doi-asserted-by":"publisher","unstructured":"Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA (1995) Clinical safety of gadopentetate dimeglumine. Radiology 196:439\u2013443. https:\/\/doi.org\/10.1148\/radiology.196.2.7617858","DOI":"10.1148\/radiology.196.2.7617858"},{"key":"5737_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1148\/radiol.15150025","volume":"275","author":"RJ McDonald","year":"2015","unstructured":"McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 275:772\u2013782. https:\/\/doi.org\/10.1148\/radiol.15150025","journal-title":"Radiology"},{"key":"5737_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.2015142690","volume":"276","author":"T Kanda","year":"2015","unstructured":"Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology 276:228\u2013232. https:\/\/doi.org\/10.1148\/radiol.2015142690","journal-title":"Radiology"},{"key":"5737_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","volume":"51","author":"N Murata","year":"2016","unstructured":"Murata N, Gonzalez-Cuyar LF, Murata K et al (2016) Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function. Invest Radiol 51:447\u2013453","journal-title":"Invest Radiol"},{"key":"5737_CR7","doi-asserted-by":"publisher","unstructured":"Ramalho J, Ramalho M, Jay M, Burke LM, Semelka RC (2016) Gadolinium toxicity and treatment. Magn Reson Imaging 34:1394\u20131398. https:\/\/doi.org\/10.1016\/j.mri.2016.09.005","DOI":"10.1016\/j.mri.2016.09.005"},{"key":"5737_CR8","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"P Marckmann","year":"2006","unstructured":"Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359\u20132362. https:\/\/doi.org\/10.1681\/ASN.2006060601","journal-title":"J Am Soc Nephrol"},{"key":"5737_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"T Grobner","year":"2005","unstructured":"Grobner T (2005) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104\u20131108. https:\/\/doi.org\/10.1093\/ndt\/gfk062","journal-title":"Nephrol Dial Transplant"},{"key":"5737_CR10","doi-asserted-by":"publisher","first-page":"W17","DOI":"10.2214\/AJR.11.8144","volume":"199","author":"R Kaewlai","year":"2012","unstructured":"Kaewlai R, Abujudeh H (2012) Nephrogenic Systemic Fibrosis. AJR Am J Roentgenol 199:W17\u2013W23. https:\/\/doi.org\/10.2214\/AJR.11.8144","journal-title":"AJR Am J Roentgenol"},{"key":"5737_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3410\/M2-84","volume":"2","author":"IM Braverman","year":"2010","unstructured":"Braverman IM, Cowper S (2010) Nephrogenic systemic fibrosis. F1000 Med Rep 2:1\u20134. https:\/\/doi.org\/10.1111\/j.1617-0830.2007.00110.x","journal-title":"F1000 Med Rep"},{"key":"5737_CR12","unstructured":"European Medicines Agency (2010) Assessment report for Gadolinium-containing contrast agents. Available via http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/gadolinium_31\/WC500099538.pdf . Accessed 13 Apr 2017"},{"key":"5737_CR13","unstructured":"Center for Drug Evaluation and Research (2010) Drug Safety and Availability - FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction [Internet]. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm223966.htm . Accessed 11 Dec 2015"},{"key":"5737_CR14","doi-asserted-by":"publisher","unstructured":"Stacul F, van der Molen AJ, Reimer P et al (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527\u20132541. https:\/\/doi.org\/10.1007\/s00330-011-2225-0","DOI":"10.1007\/s00330-011-2225-0"},{"key":"5737_CR15","doi-asserted-by":"publisher","unstructured":"Nyman U, Elmst\u00e5hl B, Leander P, Nilsson M, Golman K, Alm\u00e9n T (2002) Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 223:311\u2013319. https:\/\/doi.org\/10.1148\/radiol.2232010221","DOI":"10.1148\/radiol.2232010221"},{"key":"5737_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5414\/CNP75251","volume":"75","author":"K Fujisaki","year":"2011","unstructured":"Fujisaki K, Ono-Fujisaki A, Kura-Nakamura N et al (2011) Rapid deterioration of renal insufficiency after magnetic resonance imaging with gadolinium-based contrast agent. Clin Nephrol 75:251\u2013254. https:\/\/doi.org\/10.5414\/CNP75251","journal-title":"Clin Nephrol"},{"key":"5737_CR17","doi-asserted-by":"crossref","unstructured":"Akgun H, Gonlusen G, Cartwright J Jr, Suki WN, Truong LD (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130:1354\u20131357","DOI":"10.5858\/2006-130-1354-AGCMNA"},{"key":"5737_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/RLI.0000000000000227","volume":"50","author":"A Radbruch","year":"2015","unstructured":"Radbruch A, Weberling LD, Kieslich PJ et al (2015) High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images. Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol. Invest Radiol 50:805\u2013810. https:\/\/doi.org\/10.1148\/radiol.2015150337","journal-title":"Invest Radiol"},{"key":"5737_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/RLI.0000000000000206","volume":"50","author":"LD Weberling","year":"2015","unstructured":"Weberling LD, Kieslich PJ, Kickingereder P et al (2015) Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration. Invest Radiol 50:743\u2013748. https:\/\/doi.org\/10.1097\/RLI.0000000000000206","journal-title":"Invest Radiol"},{"key":"5737_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","volume":"51","author":"E Lancelot","year":"2016","unstructured":"Lancelot E (2016) Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents. Invest Radiol 51:691\u2013700. https:\/\/doi.org\/10.1097\/RLI.0000000000000280","journal-title":"Invest Radiol"},{"key":"5737_CR21","doi-asserted-by":"publisher","unstructured":"Frenzel T, Apte C, Jost G, Sch\u00f6ckel L, Lohrke J, Pietsch H (2017) Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol 52:396\u2013404. https:\/\/doi.org\/10.1097\/RLI.0000000000000352","DOI":"10.1097\/RLI.0000000000000352"},{"key":"5737_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/RLI.0000000000000339","volume":"52","author":"M Rasschaert","year":"2016","unstructured":"Rasschaert M, Id\u00e9e JM, Robert P et al (2016) Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. Invest Radiol 52:255\u2013264. https:\/\/doi.org\/10.1097\/RLI.0000000000000339","journal-title":"Invest Radiol"},{"key":"5737_CR23","unstructured":"European Medicines Agency (2017) EMA\u2019s final opinion confirms restrictions on use of linear gadolinium agents in body scans [Internet]. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2017\/07\/news_detail_002780.jsp&mid=WC0b01ac058004d5c1 . Accessed 2 Aug 2017"},{"key":"5737_CR24","doi-asserted-by":"publisher","unstructured":"Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M (2016) Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol 51:661\u2013665. https:\/\/doi.org\/10.1097\/RLI.0000000000000318","DOI":"10.1097\/RLI.0000000000000318"},{"key":"5737_CR25","doi-asserted-by":"publisher","unstructured":"Burke LM, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka RC (2016) Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. Magn Reson Imaging 34:1078\u20131080. https:\/\/doi.org\/10.1016\/j.mri.2016.05.005","DOI":"10.1016\/j.mri.2016.05.005"},{"key":"5737_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-med-063014-124936","volume":"67","author":"DJ Todd","year":"2016","unstructured":"Todd DJ, Kay J (2016) Gadolinium-Induced Fibrosis. Annu Rev Med 67:273\u2013291. https:\/\/doi.org\/10.1146\/annurev-med-063014-124936","journal-title":"Annu Rev Med"},{"key":"5737_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/RMR.0000000000000095","volume":"25","author":"R Forghani","year":"2016","unstructured":"Forghani R (2016) Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 25:163\u2013169. https:\/\/doi.org\/10.1097\/RMR.0000000000000095","journal-title":"Top Magn Reson Imaging"},{"key":"5737_CR28","unstructured":"Macdonald C (2017) The Current State of MR in Vascular Access Imaging.\u00a0Presented at: UK Radiological Congress (UKRC); 2017."},{"key":"5737_CR29","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jmri.25486","volume":"45","author":"P Soyer","year":"2017","unstructured":"Soyer P, Dohan A, Patkar D, Gottschalk A (2017) Observational Study on the Safety Profile of Gadoterate Meglumine in 35,499 Patients: The SECURE Study. J Magn Reson Imaging 45:988\u2013997. https:\/\/doi.org\/10.1002\/jmri.25486","journal-title":"J Magn Reson Imaging"},{"key":"5737_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004424-199502000-00002","volume":"30","author":"M Oudkerk","year":"1995","unstructured":"Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75\u201378","journal-title":"Invest Radiol"},{"key":"5737_CR31","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00330-012-2705-x","volume":"23","author":"G Deray","year":"2013","unstructured":"Deray G, Rouviere O, Bacigalupo L et al (2013) Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 23:1250\u20131259. https:\/\/doi.org\/10.1007\/s00330-012-2705-x","journal-title":"Eur Radiol"},{"key":"5737_CR32","doi-asserted-by":"publisher","unstructured":"Perrotta G, Metens T, Absil J, Lemort M, Manto M (2017) Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study. J Neurol 264:2277\u20132283. https:\/\/doi.org\/10.1007\/s00415-017-8631-8","DOI":"10.1007\/s00415-017-8631-8"},{"key":"5737_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2016.8096","volume":"316","author":"B Welk","year":"2016","unstructured":"Welk B, McArthur E, Morrow SA et al (2016) Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 316:96\u201398. https:\/\/doi.org\/10.1001\/jama.2016.8096","journal-title":"JAMA"},{"key":"5737_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/RLI.0000000000000145","volume":"50","author":"T Lauenstein","year":"2015","unstructured":"Lauenstein T, Ramierz-Garrido F, Kim YH et al (2015) Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment. Invest Radiol 50:416\u2013422","journal-title":"Invest Radiol"},{"key":"5737_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1055\/s-0033-1356403","volume":"186","author":"JT Heverhagen","year":"2014","unstructured":"Heverhagen JT, Krombach GA, Gizewski E (2014) Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis. Rofo 186:661\u2013669. https:\/\/doi.org\/10.1055\/s-0033-1356403","journal-title":"Rofo"},{"key":"5737_CR36","doi-asserted-by":"publisher","unstructured":"Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G (2009) Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency. Radiology 250:618\u2013628. https:\/\/doi.org\/10.1148\/radiol.2503080253","DOI":"10.1148\/radiol.2503080253"},{"key":"5737_CR37","doi-asserted-by":"crossref","unstructured":"Spinosa DJ, Angle JF, Hagspiel KD, Kern JA, Hartwell GD, Matsumoto AH (2000) Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11:35\u201343","DOI":"10.1016\/S1051-0443(07)61275-5"},{"key":"5737_CR38","doi-asserted-by":"crossref","unstructured":"Rieger J, Sitter T, Toepfer M, Linsenmaier U, Pfeifer KJ, Schiffl H (2002) Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17:824\u2013828","DOI":"10.1093\/ndt\/17.5.824"},{"key":"5737_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s13239-017-0317-y","volume":"8","author":"EA Murphy","year":"2017","unstructured":"Murphy EA, Ross RA, Jones RG et al (2017) Imaging in Vascular Access. Cardiovasc Eng Technol 8:255\u2013272. https:\/\/doi.org\/10.1007\/s13239-017-0317-y","journal-title":"Cardiovasc Eng Technol"},{"key":"5737_CR40","doi-asserted-by":"publisher","unstructured":"Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE (2011) Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. J Am Acad Dermatol 65:1095\u20131106.e7. https:\/\/doi.org\/10.1016\/j.jaad.2010.08.041","DOI":"10.1016\/j.jaad.2010.08.041"},{"key":"5737_CR41","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","volume":"28","author":"AJ Molen van der","year":"2018","unstructured":"van der Molen AJ, Reimer P, Dekkers IA et al (2018) Post-contrast acute kidney injury \u2013 Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors. Eur Radiol 28:2845\u20132855. https:\/\/doi.org\/10.1007\/s00330-017-5246-5","journal-title":"Eur Radiol"},{"key":"5737_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1525-139X.2006.00152.x","volume":"19","author":"DM DeHoratius","year":"2006","unstructured":"DeHoratius DM, Cowper SE (2006) Nephrogenic systemic fibrosis: An emerging threat among renal patients. Semin Dial 19:191\u2013194. https:\/\/doi.org\/10.1111\/j.1525-139X.2006.00152.x","journal-title":"Semin Dial"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5737-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5737-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5737-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T02:31:59Z","timestamp":1662172319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5737-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["5737"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5737-z","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Prof. J. G. Houston.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: Guerbet. LY is currently receiving PhD sponsorship, while SM and GH have previously received research and educational support grants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because the data controller, Health Informatics Centre, University of Dundee, has approval to use anonymised patient data for the purposes of population-based health research such as the one conducted in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Whilst this study was performed only on patient data, Institutional Review Board approval was obtained from the East of Scotland Research Ethics Committee and NHS Caldicott Guardian","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 Retrospective\u2022 Observational\u2022 Performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}